Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.
AbCellera, a Canada-based developer of an antibody drug discovery platform based on University of British Columbia research, floated on the Nasdaq Global Select Market on Friday in a $483m initial public offering that also provided an exit to University of Minnesota.
The company priced just over 24.1 million shares, upsized from 23 million, at $20 each, above the $17 to $18 range it set for the offering. Its shares opened at $61 on Friday and closed at $58.90 to…
